menu
    • menu

    Company profile for Pyramid Bio

    NEW Drugs in Dev: 4
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Pyramid Biosciences is dedicated to discovering and developing targeted therapeutics for a wide range of disorders that are regulated by the tropomyosin receptor kinase (TRK) family. By precisely and selectively modulating the actions of these fundamental cell surface receptors, we can control the key signaling pathways responsible for a patient’s disease, condition or symptoms.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Pyramid BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    303 Wyman St, Suite 300 Waltham, MA 02451
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://pyramidbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pyramid Announces Appointment of Amy Driver as Business Development Leader
    Pyramid Announces Appointment of Amy Driver as Business Development Leader

    12 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230912489861/en

    BUSINESSWIRE
    12 Sep 2023
    Share Share
    Pyramid deviates from TRK with deal for rival to Gilead ADC
    Pyramid deviates from TRK with deal for rival to Gilead ADC

    14 Apr 2023

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/astrazeneca-gilead-get-new-challenger-pyramid-deviates-trk-bag-antibody-drug-conjugate

    FIERCE BIOTECH
    14 Apr 2023
    Share Share
    Pyramid Bio to Present at the 2022 Jefferies London Healthcare Conference
    Pyramid Bio to Present at the 2022 Jefferies London Healthcare Conference

    03 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221103005330/en

    BUSINESSWIRE
    03 Nov 2022
    Share Share
    Pyramid Biosciences Names Biren Amin as Chief Financial and Strategy Officer
    Pyramid Biosciences Names Biren Amin as Chief Financial and Strategy Officer

    07 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220907005480/en

    BUSINESSWIRE
    07 Sep 2022
    Share Share
    Pyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDA
    Pyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDA

    06 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220706005039/en

    BUSINESSWIRE
    06 Jul 2022
    Share Share
    Pyramid Bio, Caris Collaborate for Trial in NTRK Fusion Solid Tumors
    Pyramid Bio, Caris Collaborate for Trial in NTRK Fusion Solid Tumors

    10 Mar 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/pyramid-biosciences-and-caris-life-sciences-announce-mi-trials-collaboration-for-clinical-trial-matching-in-support-of-study-for-patients-with-ntrk-fusion-solid-tumors-301499855.html

    PRNEWSWIRE
    10 Mar 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search